Background. The incidence of teenage pregnancy is increasing in the world. It is a high-risk condition leading to adverse perinatal and obstetric outcomes. This study aims to evaluate the obstetric and perinatal outcomes of teenage pregnancy in Indonesian population. Method. A retrospective study was conducted to evaluate obstetric and perinatal outcomes among teenagers and average maternal age (AMA) women. We assessed all singleton live pregnancies during the year period of 2013 in Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia. Results. We studied 1,676 eligible subjects during the one-year period in our centre. The prevalence of teenage pregnancy (12 to 19 years old) was 11.40% (191/1676). We found higher prevalence of eclampsia (AOR: 4.03; 95% CI: 1.73–9.39), preterm delivery (AOR: 1.5; 95% CI: 0.88–2.53), anaemia at labour (AOR: 2.42; 95% CI: 1.60–3.67), postpartum haemorrhage (AOR: 2.59; 95% CI: 0.86–7.37), and low birth weight (AOR: 2.28; 95% CI: 1.60–3.25) among teenagers. However, caesarean section was found to be significantly lower among teenage pregnancies. Conclusion. Teenage pregnancy carries significant obstetric complications that should draw physicians’ serious attention. A holistic, comprehensive antenatal, and preventive program should be conducted to prevent teenage pregnancy-related adverse outcomes.
Background: Polycystic ovary syndrome (PCOS) is an endocrinopathic disorder most commonly experienced by women of reproductive age, and it is characterized by a low-grade chronic inflammatory condition. Excessive fat deposit has been long considered as an etiological factor in the pathogenesis of this inflammatory condition. Currently, body mass index (BMI) or percentage of body fat is used as a marker to assess the body fat composition of a person. Objective: To determine whether BMI or body fat percentage (BFP) can be used as a better marker for measuring inflammation related to body fat accumulation in polycystic ovary syndrome patients. Materials and Methods: This study took place at the Center for Reproductive Medicine, Yasmin Clinic, Cipto Mangunkusumo Hospital from January to December 2015. In this cross-sectional study, 32 reproductive age women with PCOS according to the Rotterdam criteria (2003) participated. Women with hyperandrogenism caused by non-classic congenital adrenal hyperplasia, pregnant and lactating women, etc., were excluded. Some variables such as BMI, clinical hyperandrogenism sign, BFP, and inflammatory markers were assessed and statistically analyzed. Results: From a total of 32 subjects of the study, BFP had a significant positive correlation with procalcitonin levels (r=0.35; p=0.048), while BMI did not (r=0.27; p=0.131). Conclusion: BFP can be used as a better marker for measuring inflammation related to body fat accumulation in PCOS subjects.
Background Fetal supraventricular tachycardia (SVT) is the most common fetal tachyarrhythmia and can cause fetal heart failure and intrauterine death. The management varies within institution and usually based on published case series, institutional experience. Case Summary Fetal SVT with hydrops (ascites and subcutaneous edema) was diagnosed at 26 weeks of gestational age. The first direct injection of fetal amiodarone into the umbilical vein resulted in temporary cardioversion to the sinus rhythm and mild transient maternal adverse event. The second direct fetal amiodarone to the fetal peritoneal cavity resulted in conversion to sinus rhythm, resolution of fetal hydrops, and normal fetal growth until delivery at 39 weeks gestational age. Discussion Treatment of fetal SVT often requires prolonged maternal antiarrhythmic treatment and carries a significant risk of maternal adverse events. Direct fetal antiarrhythmic treatment often requires achieving adequate therapeutic drugs, especially in hydropic fetus. Amiodarone is one of drugs options for fetal SVT with hydrops because it been shown to be highly effective with low fetal mortality. Continuous vital sign and ECG monitoring should be performed during direct fetal antiarrhythmic administration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.